Dr. Lundell explains why serum testing is unreliable for patients on transdermal or pellet hormone therapy (fat‑soluble hormones bypass the liver, accumulate in adipose tissue, and bind red blood cells), and reviews the Doctor’s Data hormone testing options—saliva (Comprehensive Saliva Hormone Panel with melatonin), urine (HUMAP metabolite profile), and a Basic Hormone Profile for cost‑effective follow‑up.
He covers practical monitoring strategies, HPA axis assessment with emphasis on morning cortisol, the gut–gonadal axis and its clinical implications, and a case of menopausal overtreatment; he also critiques the claim that exogenous testosterone protects women from breast cancer.
Learning Objectives:
1. Navigate the Doctor’s Data hormone testing menu and select the appropriate panel based on clinical presentation, treatment monitoring needs, and cost considerations
2. Explain why morning cortisol is the most clinically significant marker for HPA axis dysregulation and identify evidence-based interventions for elevated nighttime cortisol
3. Describe the gut-gonadal axis and its implications for fertility, menopause, andropause, PCOS, and endometriosis in clinical practice
4. Differentiate between blood, urine, and saliva hormone testing and articulate why serum testing is unreliable for monitoring parenteral hormone therapy
5. Critically evaluate the claim that exogenous testosterone is breast cancer-protective in women and implement superior evidence-based strategies for breast cancer risk reduction
References to webinars are from our accredited laboratory network. Health care providers are encouraged to explore the original source material and apply their clinical expertise when interpreting this information.